Generate QR code
Open Access
Subscription Access
Intravascular platelet activity in patients with atrial fibrillation while taking direct anticoagulants
https://doi.org/10.30629/0023-2149-2024-102-11-12-862-867
Abstract
The article presents an analysis of changes in the platelet component of the hemostatic system in patients with paroxysmal and persistent forms of atrial fibrillation while taking direct oral anticoagulants. This group of medications is used for the prevention of ischemic stroke and other systemic thromboembolic events. The number of platelets involved in aggregates was within normal limits; however, there is a tendency toward an increase in active forms of platelets in these patients.
About the Authors
T. A. Bobyleva
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia; Military Medical Academy named after S.M. Kirov (Moscow branch) of the Ministry of Defense of Russia
Russian Federation
Russian Federation
Tatyana A. Bobyleva ― Candidate of Medical Sciences, Associate Professor of the Department of Clinical Physiology and Functional Diagnostics of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia; Associate Professor of the Department of Emergency Medicine of the Military Medical Academy named after S.M. Kirov (Moscow branch) of the Ministry of Defense of Russia
Moscow
S. B. Тkachenko
Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
Russian Federation
Russian Federation
Sergey B. Tkachenko — Doctor of Medical Sciences, Professor, corresponding member of RAS, Chief of the Department of Clinical Physiology and Functional Diagnostics of the Russian Medical Academy of Continuous Professional Education of the Ministry of Health of Russia
Moscow
References
1. Arakelyan M.G., Bocheria L.A., Vasilieva E.Yu., et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. In Russian journal of cardiology. 2021;26(7):4594. (In Russian). DOI: 10.15829/1560-4071-2021-4594
2. Revishvili A.Sh., Rzaev F.G., Gorev M.V. Diagnosis and treatment of atrial fibrillation: clinical recommendations. Moscow;2017:201. (In Russian)]. [Electronic resource. URL: http://www.infarkt.ru/d/38025/d/2017_diagnostika_i_lecheniye_fibrillyatsii_predserdiy.pdf?ysclid=lvp36je8ib607480453
3. Kirchhof P., Lip G.Y., Van Gelder IC. et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options — a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace. 2012;14(1):8–27. DOI: 10.1093/europace/eur241
4. Ozcan C., Strom J.B., Newell J.B. et al. Incidence and predictors of atrial fibrillation and its impact on long-term survival in patients with supraventricular arrhythmias. Europace. 2014;16(10):1508–14. DOI: 10.1093/europace/euu129
5. Stewart S., Hart C.L., Hole D.J. et al. Population prevalence, incidence and predictors of atrial fibrillation in the Renfrew Paisley study. Heart. 2001;86(5):516–21. DOI: 10.1136/heart.86.5.516
6. Filatov A.G., Tarashvili E.G. Epidemiology and social significance of atrial fibrillation. Annals of arrhythmology. 2012;9(2):5–13. (In Russian). [Electronic resource]. URL: https://arrhythmology.pro/files/pdf/AA_02_2012_005-013.pdf
7. Kolbin A.S., Mosikyan A.A., Tatarsky B.A. Socio-economic burden of atrial fibrillation in Russia: dynamics over 7 years (2010– 2017). Journal of Arrhythmology. 2018;(92):42–48. (In Russian)]. [Electronic resource]. URL: https://vestar.elpub.ru/jour/article/view/109
8. Melekhov A.V., Gendlin G.E., Alekseeva E.M. et al. Dynamics of the use of antiplatelet drugs in patients with atrial fibrillation: own data and a review of the edematous registers. Clinical Medicine (Russian journal). 2017; 23(3):116–126. (In Russian)] [Electronic resource. URL: https://medjrf.com/0869-2106/article/download/38375/25659
9. Kirchhof P., Benussi S., Kotecha D. et al. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organisation (ESO). Eur. Heart J. 2016;37(38):2893–2962. DOI: 10.1093/eurheartj/ehw210
10. Kirchhof Р., Bax J., Blomstrom-Lundquist C. et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ‘research perspectives in AF’. Eur. Heart J. 2009;30(24):2969–77c. DOI: 10.1093/eurheartj/ehp235
11. Abed H.S., Samuel C.S., Lau D.H. et al. Obesity results in progressive atrial structural and electrical remod-eling: Implications for atrial fibrillation. Heart Rhythm. 2013;10(1):90–100. DOI: 10.1016/j.hrthm.2012.08.043
12. Bapat A., Anderson C.D., Ellinor P.T. et al. Genomic basis of atrial fibrillation. Heart. 2018;104(3):201–206. DOI: 10.1136/heartjnl-2016-311027
13. Gallagher C., Hendriks J.M.L., Elliott A.D. et al. Alcohol and incident atrial fibrillation – A systematic review and meta-analysis. Int. J. Cardiol. 2017;246:46–52. DOI: 10.1016/j.ijcard.2017.05.133
14. Huxley R.R., Misialek J.R., Agarwal S.K. et al. Physical Activity, Obesity, Weight Change, and Risk of Atrial Fibrillation: The Atherosclerosis Risk in Communities Study. Circ. Arrhythm. Electrophysiol. 2014;7(4):620–5. DOI: 10.1161/CIRCEP.113.001244
15. Liu T., Korantzopoulos P. Xu G. et al. Association between angiotensinconvertingenzyme insertion/deletion gene polymorphism and atrial fibrillation: a meta-analysis. Europace. 2011;13(3):346–54. DOI: 10.1093/europace/euq407
16. Mitchell G.F., Vasan R.S., Keyes M.J. et al. Pulse Pressure and Risk of New-Onset Atrial Fibrillation. JAMA. 2007;297(7):709–715. DOI: 10.1001/jama.297.7.709
17. Lip G.Y., Frison L., Halperin J.L. et al. Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort. Stroke. 2010;41(12):2731–8. DOI: 10.1161/STROKEAHA.110.590257
18. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Russian Journal of Cardiology. 2021;26(9):4701. (In Russian). DOI: 10.15829/1560-4071-2021-4701
19. Kobalava Z.D., Lazarev P.V., Fedorova D.N. Cognitive Dysfunction at the Background of Atrial Fibrillation: Clinical-Pathological Aspects, Diagnostics and Prevention, Issues of the Application of Anticoagulant Therapy. Kardiologiia. 2019;59(10):66–77. (In Russian). DOI: 10.18087/cardio.2019.10. n612
20. European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery; Camm A.J. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 2010;31(19):2369–429. DOI: 10.1093/eurheartj/ehq278
21. Renda G., Ricci F., Giugliano R.P. et al. Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease. J. Am. Coll. Cardiol. 2017;69(11):1363–1371. DOI: 10.1016/j.jacc.2016.12.038
22. Sherman D.G., Kim S.G., Boop B.S. et al. Occurrence and characteristics of stroke events in the atrial fibrillation followup investigation of sinus rhythm management (AFFRIM) study. Arch. Intern. Med. 2005;165(10):1185–91. DOI: 10.1001/archinte.165.10.1185
23. Shitikova A.S. Morphological assessment of increased intravascular platelet activity. 1996:17. (In Russian).
Review
For citations:
Bobyleva T.A., Тkachenko S.B. Intravascular platelet activity in patients with atrial fibrillation while taking direct anticoagulants. Clinical Medicine (Russian Journal). 2024;102(11-12):862-867. (In Russ.) https://doi.org/10.30629/0023-2149-2024-102-11-12-862-867
Views:
117
Email this article 